Amerikaanse aandelen « Terug naar discussie overzicht

BioElectronics Cooperation (BIEL)

978 Posts, Pagina: « 1 2 3 4 5 6 ... 40 41 42 43 44 45 46 47 48 49 » | Laatste
[verwijderd]
0

BioElectronics Corp.
FREDERICK, MD--(Marketwire - November 16, 2009) - BioElectronics Corp. (PINKSHEETS: BIEL) today announced that its disposable drug-free anti-inflammatory devices proved to be significantly more effective than acetaminophen in a clinical study of Delayed Onset Muscle Soreness (DOMS).
The study tested the effectiveness of ActiPatch® Therapy versus acetaminophen in reducing the pain of Delayed Onset Muscle Soreness, a condition associated with increased physical exertion.

Bron: www.marketwire.com/press-release/Bioe...
[verwijderd]
0
quote:

welshterrier schreef:

weer down hier vandaag 0,0800
zakt wel erg ver weg hier.
word weer interessant om op te pikken.

0,0445 -0,0045 -9,18%
aldel
0
Dit aandeel zal voor de FDA beslissing flink stijgen en als in Q3 de financiele positie wordt weergeven zullen veel grote beleggers ook inzien dat BIEL een goede investering is.
Is in de afgelopende dagen voor de 15 dec flink naar beneden gekelderd.
Demenkovets
0
Mooi herstel vandaag, +30%. Zonder nieuws, maar was bij mijn weten ook zonder nieuws zo hard gedaald.
Demenkovets
0
BioElectronics to Become Fully Reporting Company
With Financial Audit Nearing Completion BioElectronics to Offer Full Financials and Increased Transparency to Investors

* Press Release
* Source: BioElectronics Corporation
* On 10:00 am EST, Monday December 14, 2009

FREDERICK, MD--(Marketwire - 12/14/09) - BioElectronics Corp. (Pinksheets:BIEL - News), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the Company would soon become a fully reporting company. The related filings will offer investors in BioElectronics full transparency into the Company's financials and financial operations.

"As we indicated several months ago, BioElectronics has engaged a professional auditing firm to review our financials in order to provide our investors, distributors and other stakeholders an accurate and unbiased evaluation of our financial position. I am happy to announce today that the audit is now almost complete and that no major issues have been raised. We are expecting the auditing firm to issue its report over the very short term," commented Andrew Whelan, CEO of BioElectronics.

The completion of the audit and the availability of the auditor's report will allow BioElectronics to soon file the required documentation in order to become a fully reporting company.

Mr. Whelan continued, "Over the past few quarters we have made great strides in improving our financial condition. We have paid off all of our institutionally owned convertible debt, greatly improved our working capital position, and significantly improved our financial ratios. We are very proud of our current balance sheet and the progress we have made during this period. As a result, we believe we are very well positioned to manage the meaningful revenue growth we expect during 2010 and beyond."
Demenkovets
0
BioElectronics Ends 2009 with International Product and Partner Gains

Source: BioElectronics Corp. On Wednesday December 30, 2009, 10:00 am EST

FREDERICK, Md.--(BUSINESS WIRE)--BioElectronics Corp. (PINKSHEETS: BIEL - News), the maker of inexpensive, disposable, drug-free anti-inflammatory devices, today announces product gains in the international market as well as new international distributor and marketing partnerships. As a result, BioElectronics is expecting significant gains in international markets throughout 2010.

Mr. Andrew Whelan, CEO of BioElectronics provides the following update to investors and other stakeholders:

“Earlier in 2009, we had stated that our corporate priorities were the completion of clinical studies, United States Food and Drug Administration (FDA) filings and the building of our brands. I am pleased to say this management team has helped BioElectronics make excellent strides in these areas. This year we completed several major studies, which we filed in support of our FDA applications. Over the past two months our staff has worked diligently on additional applications seeking reclassification of our products from Class III to Class II. We believe this application contains compelling evidence that our products are not only effective, but are also safe. We remain confident that FDA clearance will be granted for our products. We believe our meeting, which is scheduled with the FDA for January, will allow us to make significant progress towards that goal. In the meantime, our international marketing efforts are moving into high gear with significant progress already being realized.

“Today, we are announcing several significant international orders and partnerships. Our new distributor in Columbia, Health Tools S.A., has placed an order for both Allay, ActiPatch, and HealFast in support of the Latin American direct response TV campaign and its direct sales operations. We are also anticipating additional orders from our other Latin American partners. Additionally, our Turkey distributor has made a substantial commitment for product in support of direct response TV marketing campaigns in that region.

“The management team has also been spending a considerable amount of time fostering relationships to drive sales in Asia. We recently finished our television advertising spots targeting China and those will be tested during the first quarter of 2010. Over the next several months members of the team will visit our Chinese marketing partner, Chinese government officials and television station executives in China. We view this as a very exciting revenue generation opportunity. We are also happy to announce we have completed negotiations with a well financed public company that will act as our marketing partner in Japan. Over the next few days we are expecting this partner to place a significant pre-order for product. We have long been excited about the Japanese market and believe it could ultimately be our largest market outside the United States.

“The significant revenues we expect from these efforts will allow us to further strengthen our year-end balance sheet and position us well for substantial revenue growth in 2010 and beyond.”
Demenkovets
0
BioElectronics Signs Deal to Enter Japanese Market

Order from YesDTC Holdings is the Single Largest Order in Company History

Press Release Source: BioElectronics Corp. On Monday January 25, 2010, 10:00 am

FREDERICK, Md.--(BUSINESS WIRE)--BioElectronics Corp. (PINKSHEETS: BIEL - News), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the signing of a contract with YesDTC Holdings, Inc. (YESD.OB) to enter the Japanese market and receipt of the single largest product order and revenue commitment in company history.

Shipments of initial products are expected to begin in the first quarter of 2010 with additional shipments expected throughout the year.

“We are very excited about our entry into the Japanese market as we believe consumers will be highly receptive to our drug-free pain relieving and healing technology,” said Arnon Horev, BioElectronics Vice President of Marketing. “The initial order being placed via our Japanese distributor is far and away our single biggest order we have ever received and well into six figures. We plan on recognizing part of this order in Q4:09 with the remaining portions and Q1:10 and Q2:10 and to realize additional revenues through the rest of 2010. The realization of a significant portion of this revenue in Q4:09 will allow us to further strengthen our already strong balance sheet. We welcome YesDTC Holdings to our growing ranks of premium international distributors for our award winning pain relieving and healing products.”

“At BioElectronics we are aggressively moving into many international markets,” Horev said. “As we have previously indicated, we have major initiatives underway in Latin America, Europe, Canada, and China among other international markets. We are expecting to begin airing television commercials in China during the first quarter of 2010 in support of our marketing efforts in that region and we are preparing to enter the Japanese market through our new distribution partner, YesDTC Holdings.”
StephanO
0
Weer in de stijgende lijn. Ik heb dit aandeel al een geruime tijd.. Zit er al in vanaf 0.01 cent, heb het niet durven te verkopen, omdat ik verwachte dat hij eerder door zou gaan stijgen.. Nu is er in iedergeval weer sprake van een up-trent.. Ik zie nog een mooie toekomst voor dit bedrijf en zeker een leuke winst voor de mensen die hier nog in handelen..
[verwijderd]
0
FDA is nog lang niet in zicht. De verhouding van prijs een waarde kloppen niet. Grote kans dat ze weer naar oud niveu gaan.
[verwijderd]
0
BioElectronics Becomes Fully Reporting – Completes 2009 Audit, Files Form 10K with Securities and Exchange Commission
Date : 04/01/2010 @ 8:00AM
Source : Business Wire
Stock : BioElectronics Corp. (BIEL)
Quote : 0.0309 0.0 (0.00%) @ 8:34AM


BioElectronics Becomes Fully Reporting – Completes 2009 Audit, Files Form 10K with Securities and Exchange Commission

BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of its full year audit and the filing of Form 10K with the Securities and Exchange Commission. BioElectronics is now a fully reporting company.

“We have now completed our audits through full year 2009. The process of providing full transparency is very important to us and we expect to remain fully compliant and reporting moving forward,” commented Andrew Whelan, CEO of BioElectronics Corp. “The recent developments at the Company are very exciting as our international distribution continues to grow and as we continue to work through the clearance process with the U.S. FDA. We are especially excited about the strength of our balance sheet, which shows strong financial ratios and a significant level of debt repayment throughout 2009. We believe BioElectronics is now very well positioned to move into the revenue growth phase we envision for the rest of this year and into next.”

About BioElectronics Corporation

BioElectronics Corporation
is the maker of ActiPatch® Therapy, RecoveryRx(TM) Devices, HealFast(TM) Therapy (www.healfasttherapy.com) and the Allay(TM) family of inexpensive, disposable drug-free anti-inflammatory devices. For more information please see www.BioElectronicsCorp.com.
978 Posts, Pagina: « 1 2 3 4 5 6 ... 40 41 42 43 44 45 46 47 48 49 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
894,61  +3,48  +0,39%  09:42
 Germany40^ 18.237,80 +0,34%
 BEL 20 3.958,82 +0,76%
 Europe50^ 4.976,65 +0,40%
 US30^ 38.854,63 +0,03%
 Nasd100^ 18.062,54 -0,15%
 US500^ 5.177,78 -0,01%
 Japan225^ 38.876,22 +0,04%
 Gold spot 2.320,88 -0,12%
 EUR/USD 1,0766 -0,03%
 WTI 78,43 -0,22%
#/^ Index indications calculated real time, zie disclaimer

Aandelenadviezen van IEX.nl

  1. Premium
    Advieswijziging ASML
  2. Premium
    Iets langer geduld met Besi
  3. Premium
    Tijd om het aandeel Adyen op te vissen?
  4. Premium
    Uitstekende cijfers Flow Traders
  5. Premium

Stijgers

Kendrion +3,77%
Basic-Fit +3,32%
Van Lanschot ... +2,82%
VIVORYON THER... +2,60%
Air France-KLM +2,38%

Dalers

ArcelorMittal -1,40%
PROSUS -1,10%
NX FILTRATION -0,99%
Avantium -0,75%
BAM -0,65%

EU stocks, real time, by Cboe Europe Ltd.; Other, Euronext & US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront